This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a novel circulating tumor DNA (ctDNA) assay technology by Binary Genomics, Inc. to monitor the efficacy of immunotherapy treatments for non-small cell lung cancer. The $398,040 award over 18 months will enable the company to evaluate the analytical and baseline clinical performance of their ctDNA assay, which aims to address limitations of existing mutation-based approaches by leveraging epigenetic features present across cancer genomes. This proof-of-concept project will benchmark the new ctDNA assay against commercial mutation-based tests to justify further development and commercialization of the technology, with the goal of providing clinicians improved tools for monitoring patient response to immunotherapy.
Generated 7/16/24, 2:25 AM